A detailed history of Stifel Financial Corp transactions in Biogen Inc. stock. As of the latest transaction made, Stifel Financial Corp holds 47,554 shares of BIIB stock, worth $7.42 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
47,554
Previous 46,686 1.86%
Holding current value
$7.42 Million
Previous $10.8 Million 14.83%
% of portfolio
0.01%
Previous 0.01%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$189.07 - $236.8 $164,112 - $205,542
868 Added 1.86%
47,554 $9.22 Million
Q2 2024

Aug 13, 2024

SELL
$190.52 - $236.72 $2.44 Million - $3.03 Million
-12,789 Reduced 21.5%
46,686 $10.8 Million
Q1 2024

May 13, 2024

BUY
$212.02 - $267.71 $1.66 Million - $2.1 Million
7,827 Added 15.15%
59,475 $12.8 Million
Q4 2023

Feb 12, 2024

SELL
$222.59 - $267.94 $907,944 - $1.09 Million
-4,079 Reduced 7.32%
51,648 $13.4 Million
Q3 2023

Nov 13, 2023

BUY
$253.3 - $285.89 $2.48 Million - $2.8 Million
9,809 Added 21.36%
55,727 $14.3 Million
Q2 2023

Aug 14, 2023

BUY
$275.25 - $318.06 $1.71 Million - $1.98 Million
6,213 Added 15.65%
45,918 $13.1 Million
Q1 2023

May 12, 2023

SELL
$256.56 - $292.34 $469,761 - $535,274
-1,831 Reduced 4.41%
39,705 $11 Million
Q4 2022

Feb 13, 2023

BUY
$252.44 - $306.72 $1.36 Million - $1.66 Million
5,399 Added 14.94%
41,536 $11.5 Million
Q3 2022

Nov 14, 2022

SELL
$194.69 - $268.46 $377,503 - $520,543
-1,939 Reduced 5.09%
36,137 $9.65 Million
Q2 2022

Aug 15, 2022

SELL
$187.54 - $223.02 $1.3 Million - $1.54 Million
-6,919 Reduced 15.38%
38,076 $7.76 Million
Q1 2022

May 13, 2022

BUY
$193.77 - $244.14 $226,710 - $285,643
1,170 Added 2.67%
44,995 $9.48 Million
Q4 2021

Feb 14, 2022

SELL
$223.92 - $287.77 $765,806 - $984,173
-3,420 Reduced 7.24%
43,825 $10.5 Million
Q3 2021

Nov 15, 2021

SELL
$282.99 - $369.05 $761,243 - $992,744
-2,690 Reduced 5.39%
47,245 $13.4 Million
Q2 2021

Aug 13, 2021

SELL
$259.0 - $414.71 $2.68 Million - $4.29 Million
-10,336 Reduced 17.15%
49,935 $17.3 Million
Q1 2021

May 14, 2021

BUY
$242.95 - $284.63 $1.73 Million - $2.03 Million
7,125 Added 13.41%
60,271 $16.9 Million
Q4 2020

Feb 12, 2021

BUY
$236.26 - $355.63 $169,634 - $255,342
718 Added 1.37%
53,146 $13 Million
Q3 2020

Nov 16, 2020

SELL
$264.77 - $305.71 $481,351 - $555,780
-1,818 Reduced 3.35%
52,428 $14.9 Million
Q2 2020

Aug 14, 2020

SELL
$258.66 - $342.55 $547,324 - $724,835
-2,116 Reduced 3.75%
54,246 $14.5 Million
Q1 2020

May 14, 2020

SELL
$268.85 - $341.04 $19.5 Million - $24.7 Million
-72,541 Reduced 56.28%
56,362 $17.9 Million
Q4 2019

Feb 13, 2020

BUY
$220.06 - $304.07 $10.5 Million - $14.5 Million
47,591 Added 58.53%
128,903 $38.2 Million
Q3 2019

Nov 19, 2019

BUY
$217.44 - $243.88 $50,446 - $56,580
232 Added 0.29%
81,312 $18.9 Million
Q3 2019

Nov 13, 2019

SELL
$217.44 - $243.88 $15.4 Million - $17.3 Million
-71,007 Reduced 46.69%
81,080 $18.9 Million
Q2 2019

Aug 14, 2019

SELL
$219.29 - $241.72 $7.07 Million - $7.8 Million
-32,260 Reduced 17.5%
152,087 $35.6 Million
Q1 2019

May 14, 2019

SELL
$216.71 - $338.96 $12.7 Million - $19.9 Million
-58,595 Reduced 24.12%
184,347 $43.5 Million
Q4 2018

Feb 13, 2019

BUY
$278.5 - $352.75 $747,494 - $946,781
2,684 Added 1.12%
242,942 $73.3 Million
Q3 2018

Nov 13, 2018

BUY
$293.51 - $383.83 $5.46 Million - $7.14 Million
18,603 Added 8.39%
240,258 $84.7 Million
Q2 2018

Aug 14, 2018

BUY
$257.52 - $306.91 $3.56 Million - $4.24 Million
13,814 Added 6.65%
221,655 $64.2 Million
Q1 2018

May 11, 2018

BUY
$260.13 - $367.91 $4.76 Million - $6.73 Million
18,283 Added 9.65%
207,841 $56.8 Million
Q4 2017

Feb 14, 2018

BUY
$307.64 - $344.58 $3.83 Million - $4.29 Million
12,464 Added 7.04%
189,558 $60.5 Million
Q3 2017

Nov 13, 2017

BUY
$281.15 - $329.69 $49.8 Million - $58.4 Million
177,094
177,094 $0

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $22.5B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Stifel Financial Corp Portfolio

Follow Stifel Financial Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Stifel Financial Corp, based on Form 13F filings with the SEC.

News

Stay updated on Stifel Financial Corp with notifications on news.